Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Single dose antithymocyte globulin effectively reduces GVHD and improves survival in patient undergoing myeloablative matched sibling alloHCT.
Journal: Leukemia & lymphoma
Published: May 05, 2026
Dynamic-EASIX DRI Model: A Novel Tool for Predicting Outcomes After Allogeneic Hematopoietic Cell Transplantation.
Journal: Transplantation and cellular therapy
Published: February 08, 2026
Risk of Relapse Post Reduced Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With High-Risk Myeloid Neoplasms Based on GvHD Prophylaxis: PTCy Vs. TAC/MTX.
Journal: American journal of hematology
Published: July 27, 2025
Outcomes of Post-Transplant Rh-GCSF and Decitabine Maintenance Therapy in Patients With High-Risk Myeloid Neoplasm.
Journal: American journal of hematology
Published: March 11, 2025
Comparison of Chimerism Kinetics and Associated Outcomes in Patients Receiving Post-Transplant Cyclophosphamide Versus Methotrexate based GVHD Prophylaxis Following Allogeneic Hematopoietic Cell Transplant.
Journal: Transplantation and cellular therapy
Published: February 25, 2025
Outcomes of attenuated dose fludarabine and melphalan based conditioning regimen in patients undergoing allogeneic stem cell transplant: a propensity score-matched analysis.
Journal: Bone marrow transplantation
Published: February 23, 2025
Coronary Artery Calcification as a Predictor of Survival in Patients Receiving Post-transplant Cyclophosphamide for GVHD Prophylaxis.
Journal: Transplantation and cellular therapy
Published: January 09, 2025
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort.
Journal: Blood cancer journal
Published: December 27, 2024
Clinical outcomes of patients diagnosed with SETBP1 mutated myeloid neoplasms.
Journal: Leukemia & lymphoma
Published: November 06, 2024
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations.
Journal: Blood advances
Published: November 04, 2024
Clinicopathologic correlates and prognostic impact of lymphoid aggregates in patients with myelodysplastic syndromes.
Journal: British journal of haematology
Published: May 11, 2024
Last Updated: 09/26/2026